<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148550</url>
  </required_header>
  <id_info>
    <org_study_id>MITOHEP 6003</org_study_id>
    <secondary_id>U01DK103149</secondary_id>
    <secondary_id>U01DK103140</secondary_id>
    <secondary_id>U01DK103135</secondary_id>
    <secondary_id>U01DK084575</secondary_id>
    <secondary_id>U01DK084538</secondary_id>
    <secondary_id>U01DK084536</secondary_id>
    <secondary_id>U01DK062503</secondary_id>
    <secondary_id>U01DK062500</secondary_id>
    <secondary_id>U01DK062497</secondary_id>
    <secondary_id>U01DK062481</secondary_id>
    <secondary_id>U01DK062470</secondary_id>
    <secondary_id>U01DK062466</secondary_id>
    <secondary_id>U01DK062456</secondary_id>
    <secondary_id>U01DK062453</secondary_id>
    <secondary_id>U01DK062452</secondary_id>
    <secondary_id>U01DK062445</secondary_id>
    <secondary_id>U01DK062436</secondary_id>
    <nct_id>NCT01148550</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Mitochondrial Hepatopathies</brief_title>
  <acronym>MITOHEP</acronym>
  <official_title>Longitudinal Study of Mitochondrial Hepatopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Research Collaborative for Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbor Research Collaborative for Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aims of this study are (1) to determine the clinical phenotypes and natural
      history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype
      and phenotype, (3) to determine if circulating biomarkers reflect diagnosis and predict liver
      disease progression and survival with the native liver, (4) to determine the clinical outcome
      of these disorders following liver transplantation, and (5) to develop a repository of serum,
      plasma, urine, tissue and DNA specimens that will be used in ancillary studies. To accomplish
      these aims, the ChiLDREN investigators at clinical sites (currently 15 sites) will
      prospectively collect defined data and specimens in a uniform fashion at fixed intervals in a
      relatively large number of subjects. Clinical information and DNA samples to be collected
      from subjects and their parents will enhance the potential for meaningful research in these
      disorders. A biobank of subject specimens and DNA samples will be established for use in
      ancillary studies to be performed in addition to this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted as part of the NIH-supported Childhood Liver Disease Research
      and Education Network (ChiLDREN). ChiLDREN is investigating rare cholestatic liver diseases
      of childhood: alpha-1 antitrypsin deficiency (A1AT), Alagille's Syndrome (AGS), progressive
      familial intrahepatic cholestasis (PFIC), bile acid synthesis defects and mitochondrial
      hepatopathies (all previously studied by the Cholestatic Liver Disease Consortium [CLiC]);
      biliary atresia (previously studied by the Biliary Atresia Research Consortium [BARC]);
      neonatal hepatitis; and cystic fibrosis liver disease, which is studied by a new branch of
      ChiLDREN known as the Cystic Fibrosis Liver Disease (CFLD) Network.

      In this protocol, mitochondrial hepatopathies in children and young adults will be
      investigated. The focus will be on respiratory chain defects (RC) and defects of fatty acid
      oxidation (FAO). There is little known about the full spectrum of severity and long-term
      natural history of mitochondrial hepatopathies. Moreover, these disorders have not been
      subject to prospective, rigorous clinicopathological scrutiny.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Listing for liver transplant</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Listing for liver transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver transplantation</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Liver transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Involvement of other organ systems known to be associated with mitochondrial diseases</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Involvement of other organ systems known to be associated with mitochondrial diseases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth failure</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Growth failure (defined as weight or length Z-score for age &lt; -2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening liver function</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Worsening liver function (defined as PELD &gt;10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of portal hypertension</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Complications of portal hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Neurodevelopmental outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>Measured/assessed at baseline, 6 months, Years 1 through 10, and at time of liver transplant, liver or muscle biopsy or hospitalization for critical illness if applicable</time_frame>
    <description>Health related Quality of Life</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Acute Liver Failure</condition>
  <condition>Mitochondrial Diseases</condition>
  <condition>End Stage Liver Disease</condition>
  <condition>Respiratory Chain Deficiencies, Mitochondrial</condition>
  <condition>Disorder of Fatty Acid Oxidation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Mitochondrial Hepatopathy Disease Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma and serum samples with DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 67 children and young adults with suspected or documented hepatic RC defect or
        FAO defect between birth and 18 years old from both genders and all races and ethnic groups
        that meet inclusion/exclusion criteria as defined below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects in Group 1 (Mitochondrial Hepatopathy group) must meet all of the following
        inclusion criteria:

          1. Children and young adults with suspected or documented hepatic RC defector FAO defect
             from birth to 18 years old (through 18 years).

          2. Both genders, all races and ethnic groups.

          3. Participants must meet one of the following sets of criteria (A or B):

        A. Potential subjects presenting with acute or chronic liver disease or acute liver failure
        but who have not had a liver transplant must meet one of Clinical Criteria 1 and one of
        Clinical Criteria 2 listed below:

          1. Clinical Criteria 1 (any one of the following)

               -  1.Acute liver failure,defined as severe liver dysfunction and either 1) INR &gt;1.5
                  or prothrombin time &gt; 15 seconds with encephalopathy or 2) INR &gt; 2.0 or
                  prothrombin time &gt; 20 seconds with or without encephalopathy; occurring within 8
                  weeks of onset of illness; with no known underlying chronic liver disease, or

               -  2.Acute liver disease defined as elevated AST or ALT &gt;1.25 ULN and CK &lt;1000u/L or
                  conjugated bilirubin &gt;2.0 mg/dl and &gt;20% of total bilirubin, or

               -  3.Chronic liver disease defined as:

                    -  elevated ALT or AST (&gt;1.25 ULN) for &gt; 6 months, or

                    -  conjugated hyperbilirubinemia (conjugated [direct] &gt; 2.0 mg/dl and &gt; 20% of
                       total bilirubin) for &gt; 6 months or

                    -  clinical stigmata of chronic liver disease, including chronic hepatomegaly,
                       clinical findings or complications of cirrhosis or portal hypertension,
                       impaired liver synthetic function, intractable pruritus explainable only by
                       liver disease or end-stage liver disease, or

                    -  abnormal liver histology including hepatic fibrosis or cirrhosis,
                       microvesicular steatosis, canalicular cholestasis, ballooned granular red
                       hepatocytes (AKA onocytes), intralobular collapse/regeneration And

          2. Clinical Criteria 2 (any one of the following:

               -  1.Prior history of extra-hepatic organ involvement accompanied by any one or more
                  of the signs and symptoms associated with mitochondrial dysfunction (e.g.

        hypotonia, neuro-developmental delay, seizure disorder requiring treatment with valproic
        acid, nystagmus, cardiomyopathy, renal tubulopathy, bone marrow failure,myopathy, hearing
        loss), or

          -  2.Lactic acidosis (arterial blood or free-flowing venous blood level &gt;2.5 mmol/L or
             &gt;22.5 mg/dl at any age and increased lactate:pyruvate ratio [&gt;25.0]) or

          -  3.Hypoglycemia (blood glucose &lt;45 mg/dl on any measurement) and hypoketonuria (&lt;1+ for
             urine ketones by dipstick on urine specimen obtained within 4 hours after collecting
             blood with low glucose concentration), or

          -  4.Abnormal acyl carnitine profile, or

          -  5.Documented biochemical (enzymatic) or genetic diagnosis 3b. Potential participants
             who have undergone a liver transplantation because of acute liver failure or end stage
             liver disease due to suspected or confirmed mitochondrial hepatopathy; the
             transplantation may have been performed at a non-ChiLDREN medical center or at a
             ChiLDREN Clinical Site.

        B. Potential subjects who have already had a liver transplant must meet criteria 1 and
        either criteria 2 or criteria 3 below:

          -  1.Previous liver transplantation, AND

          -  2.Suspected mitochondrial liver disease, based upon meeting one or more of the
             following criteria:

               -  Had a prior history of extra-hepatic organ involvement accompanied by signs and
                  symptoms associated with mitochondrial dysfunction (e.g., hypotonia,
                  neuro-developmental delay, seizure disorder requiring treatment with valproic
                  acid, nystagmus, cardiomyopathy, renal tubulopathy, bone marrow failure,
                  myopathy, hearing loss), OR

               -  A prior history of lactic acidosis (arterial blood or free-flowing venous blood
                  level &gt;2.5 mmol/L or &gt;22.5 mg/dl at any age and increased lactate:pyruvate ratio
                  [&gt;25.0]), OR

               -  A prior history of hypoglycemia (blood glucose &lt;45 mg/dl on any measurement) and
                  hypoketonuria (â‰¤1+ for urine ketones by dipstick on urine specimen obtained
                  within 4 hours after collecting blood with low glucose concentration), OR

               -  A prior history of an abnormal acyl carnitine profile, OR

               -  Documented biochemical (enzymatic) or genetic diagnosis of a mitochondrial
                  disorder

          -  3.A documented (confirmed) mitochondrial disorder based upon the confirmation criteria
             specified in protocol.

        Subjects in Group 2 (Suspected Mitochondrial Hepatopathy not meeting Group 1 enrollment
        criteria) must meet the following inclusion criteria:

          1. Children and young adults with suspected hepatic RC defect or FAO defect between birth
             through 18 years but who do not meet clinical inclusion criteria listed above for
             acute or chronic liver disease or acute liver failure.

          2. Both genders, all races and ethnic groups.

        Subjects in either Group 1 or 2 must not have any of the following exclusion criteria:

          1. Inability to comply with the longitudinal follow-up described below.

          2. Failure of a family/patient to sign the informed consent/assent document or the HIPAA
             authorization form.

          3. Known Medium Chain Acyl CoA Dehydrogenase deficiency (MCAD).

          4. Other known causes of liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald J Sokol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Doo, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John C Magee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Merion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arbor Research Collaborative for Health - Data Coordinating Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peg Hill-Callahan, BS, LSW</last_name>
    <phone>734-369-9674</phone>
    <email>peg.hill-callahan@arborresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Lachance, BS</last_name>
    <phone>734-369-9963</phone>
    <email>ellen.lachance@arborresearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Goodhue, CPNP</last_name>
      <phone>323-361-4566</phone>
      <email>cgoodhue@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janelle Gonzalez</last_name>
      <phone>323-361-3113</phone>
      <email>jangonzalez@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kasper Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanda Kerker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Michail, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hite</last_name>
      <phone>720-777-4690</phone>
      <email>michelle.hite@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Darci Anderson</last_name>
      <phone>720-777-9911</phone>
      <email>darci.anderson@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Narkewicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Sokol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cara Mack, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shikha Sundram, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Van Hove, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Tory</last_name>
      <phone>404-785-1467</phone>
      <email>rita.tory@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Ngoc Ly Nguyen</last_name>
      <phone>404-727-1463</phone>
      <email>ngocly.nguyen@choa.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rene Romero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nitika Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Vos, MD, MSPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saul Karpen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M. Kelly, RN, BSN</last_name>
      <phone>312-227-3523</phone>
      <email>skelly@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Lee Bass, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estella Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Klipsch, RN</last_name>
      <phone>317-944-9605</phone>
      <email>aeye@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Molleston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Molly Bozic</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Denlinger, RN, BSN</last_name>
      <phone>513-636-7818</phone>
      <email>julie.denlinger@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Gindling, RN, BSN</last_name>
      <phone>513-803-7482</phone>
      <email>kelly.gindling@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Bezerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Palermo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Heubi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Miethke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessi Erlichman, MPH</last_name>
      <phone>215-590-2525</phone>
      <email>erlichman@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Wong</last_name>
      <phone>267-426-8412</phone>
      <email>skwong@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Piccoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Rand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathy Loomes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Bukauskas, RN</last_name>
      <phone>412-692-5180</phone>
      <email>kathryn.bukauskas@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paula Layton, RN</last_name>
      <phone>412-692-5811</phone>
      <email>paula.layton2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Squires, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Lindblad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Mazariegos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Squires, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veena Venkat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Tsai</last_name>
      <phone>832-822-3634</phone>
      <email>ct2@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurel Cavallo</last_name>
      <phone>832-822-1053</phone>
      <email>Laurel.Cavallo@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Shneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Hertel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Rutherford</last_name>
      <phone>801-585-9495</phone>
      <email>ann.rutherford@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kyle Berg</last_name>
      <phone>801-587-5670</phone>
      <email>Kyle.berg@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Guthery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyle Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Murray, MD</last_name>
      <phone>206-987-2775</phone>
      <email>karen.murray@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Young</last_name>
      <phone>(206) 987-1037</phone>
      <email>melissa.young@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Murray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Horslen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyn Shu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Simoes</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>201594</phone_ext>
      <email>vanessa.simoes@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Elena Reydman</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>201594</phone_ext>
      <email>elena.reydman@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Vicky Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria DeAngelis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Binita Kamath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Constance O'Connor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://childrennetwork.org/</url>
    <description>Childhood Liver Disease Research Network Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neonatal acute liver failure</keyword>
  <keyword>late-onset liver failure</keyword>
  <keyword>cholestasis,</keyword>
  <keyword>fatty liver,</keyword>
  <keyword>liver dysfunction,</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be transferred to NIDDK at the end of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

